Triple Peptide Vaccine


Chicago - Data involving the first 60 patients in a phase II clinical trial of a multi-epitope peptide vaccination, as combined with other agents, showed a median survival of 21 months for immunological responders as compared to 13 months in immunologic nonresponders.

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.